Today, We Take a Bold Step Toward Transforming Neurodevelopmental Care
MicroSigX is proud to announce, together with CUHK Faculty of Medicine, the launch of the world’s first AI-powered multikingdom microbiome test — MSX Metagenie®. This breakthrough technology, backed by FDA Breakthrough Device Designation, delivers ≥95% negative predictive value to help healthcare professionals rule out ASD in low-risk cases.
Today’s announcement marks the start of our pilot donation program, launching in January 2026, to provide 200 free tests for eligible preschool children in Hong Kong through local NGOs. Our goal is to reduce diagnosis bottlenecks, ease parental anxiety, and optimize medical resources for those who need them most.
“Our mission goes beyond technology. We are addressing a critical gap in early neurodevelopmental care—helping families find clarity sooner and enabling health systems to allocate resources more effectively.”
Rachel Fan, CEO, MicroSigX
To learn more:
CUHK Press Release: https://www.med.cuhk.edu.hk/press-releases/cuhk-and-microsigx-partner-to-launch-a-breakthrough-test-aiding-early-autism-diagnosis-offering-200-free-test-quotas
MicroSigX: www.microsigx.com
#MicroSigX #MSXMetagenie #Innovation #ASD #Healthcare #Impact #創新 #自閉症 #醫療 #社會影響
